01 February 2017 2 Min Read
Roche expects competition to cut into profit
Drug maker says spending on new drugs is likely to stall its margin growth as it grapples with patent expirations of some cancer medicines
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In